近年来随着创新药物研发投入的不断增长,抗癌药物的种类愈发多样,其安全性问题也引起了更多的关注。然而,相比于常见的肝肾毒性及免疫原性和免疫毒性等,抗癌药物的甲状腺毒性未获得足够的重视。本文作者通过总结目前美国FDA已批准上市的明确具有甲状腺毒性的代表性抗癌药物及其毒作用机制,包括免疫检查点抑制剂、酪氨酸激酶抑制剂、沙利度胺同系物、贝沙罗汀等,探讨非临床毒理研究对于临床甲状腺相关不良反应的预测价值和不足,为后续抗癌药物甲状腺毒性的评价提供参考。

[1] RAZVI S,JABBAR A,PINGITORE A,et al.Thyroid hormones and cardiovascular function and diseases[J].J Am Coll Cardiol,2018,71(16):1781-1796.
[2] RIGUETTO C M,NETO A M,TAMBASCIA M A,et al.The relationship between quality of life,cognition,and thyroid status in Graves' disease[J].Endocrine,2019,63(1):87-93.
[3] KOREVAAR T I,MUETZEL R,MEDICI M,et al.Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood:a population-based prospective cohort study[J].Lancet Diabetes Endocrinol,2016,4(1):35-43.
[4] DERAKHSHAN A,PEETERS R P,TAYLOR P N,et al.Association of maternal thyroid function with birthweight:a systematic review and individual-participant data meta-analysis[J].Lancet Diabetes Endocrinol,2020,8(6):501-510.
[5] POTTIER C,FRESNAIS M,GILON M,et al.Tyrosine kinase inhibitors in cancer:breakthrough and challenges of targeted therapy[J].Cancers,2020,12(3):731-748.
[6] JANNIN A,PENEL N,LADSOUS M,et al.Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders[J].Crit Rev Oncol Hemat,2019,141:23-35.
[7] JEAN G W,MANI R M,JAFFRY A,et al.Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers[J].JAMA Oncology,2016,2(4):529-534.
[8] BHATTACHARYA S,GOYAL A,KAUR P,et al.Anticancer drug-induced thyroid dysfunction[J].Eur Endocrinol,2020,16(1):32-39.
[9] RYDER M,CALLAHAN M,POSTOW M,et al.Endocrine-related adverse events following ipilimumab in patients with advanced melanoma:a comprehensive retrospective review from a single institution[J].Endocr Relat Cancer,2014,21(2):371-381.
[10] THOMAS D A,KANTARJIAN H M.Current role of thalidomide in cancer treatment[J].Curr Opin Oncol,2000,12(6):564-573.
[11] BADROS A Z,SIEGEL E,BODENNER D,et al.Hypothyroidism in patients with multiple myeloma following treatment with thalidomide[J].Am J Med,2002,112(5):412-413.
[12] MAKITA N,MANAKA K,SATO J,et al.Bexarotene-induced hypothyroidism:Characteristics and therapeutic strategies[J].Clin Endocrinol,2019,91(1):195-200.
[13] 萧惠来.FDA发布的"药物内分泌毒性非临床评价指导原则"介绍[J].药物评价研究,2016,39(1):19-22.
[14] DOSIOU C.Thyroid and fertility:recent advances[J].Thyroid,2020,30(4):479-486.
[15] PREZIOSO G,GIANNINI C,CHIARELLI F.Effect of thyroid hormones on neurons and neurodevelopment[J].Horm Res Paediat,2018,90(2):73-81.
[16] LEE S Y,PEARCE E N.Testing,monitoring,and treatment of thyroid dysfunction in pregnancy[J].J Clin Endocr Metab,2021,106(3):883-892.
[17] MOELLER L C,FÜHRER D.Thyroid hormone,thyroid hormone receptors,and cancer:a clinical perspective[J].Endocr Relat Cancer,2013,20(2):R19-29.
[18] WENG C H,OKAWA E R,ROBERTS M B,et al.Breast cancer risk in postmenopausal women with medical history of thyroid disorder in the women's health initiative[J].Thyroid,2020,30(4):519-530.